Tempus AI Earnings Call Highlights Growth and Scale

Tempus AI reported Q3 revenue of $412M, up 23% YoY. Diagnostics and oncology revenues grew 20% and 28%, respectively. The company highlighted major collaborations with BMS, Moderna, and Merck, and expects positive adjusted EBITDA. Management acknowledged reimbursement risks and Personalis' current losses but remains optimistic about growth opportunities, including a $20B MRD market.

Original reporting
Published Nov 15, 2026, 12:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 1:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
4/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The recap reinforces prior expectations but provides no actionable insight.

02

Market read

The article is a post‑earnings summary with no new data; limited trading relevance.

03

What to watch

None; all material points were covered in the original earnings release.

Relevance 4/10Novelty 2/10Timing: post‑earnings recap

Background

Tempus AI reported 23% revenue growth and positive adjusted EBITDA for Q3, with several partnership announcements.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

The article recaps Tempus AI's Q3 earnings call, repeating revenue and EBITDA figures already released 13 days earlier.

Expected impact

likely flat as market has priced the earnings already.

Evidence & confidence

All financial metrics were disclosed in the prior earnings release; the article adds no fresh information.

Market effects

None; the biotech data‑analytics sector sees no new development.

None; US market already incorporated the earnings.

Low

Counterpoint

No contrarian angle; the story offers no new upside or downside.

Key entities

  • Tempus AI, Inc.

    Provider of data and AI services for oncology and other health areas.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.